<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00218036</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-09262-8</org_study_id>
    <secondary_id>P50DA009262-08</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00218036</nct_id>
  </id_info>
  <brief_title>Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8</brief_title>
  <official_title>Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine two medications, modafinil and citalopram, in the
      treatment of cocaine dependent individuals who are maintained on methadone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 24-week, randomized, double-blind, placebo-controlled study examining two doses of
      modafinil (200 and 400 mg) and citalopram (20 and 40 mg) in the treatment of methadone
      maintained cocaine dependent individuals.

      Participants will first be given methadone to determine its tolerated and effective doses.
      Most participants will be able to reach a stable dose of methadone within 7 to 10 days of
      methadone initiation. When 80% of the projected dose of methadone has been achieved,
      participants will begin the medication regimen of modafinil or citalopram. Modafinil will be
      given over a 7-day period. Dosing of modafinil will begin at 200 mg and, depending on the
      individual, may increase to 400 mg. Citalopram will be given in increasing doses, starting at
      20 mg and increasing to 40mg.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2006</start_date>
  <completion_date type="Anticipated">July 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed abstinence from cocaine</measure>
    <time_frame>12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retention</measure>
    <time_frame>12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Compliance</measure>
    <time_frame>12 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cocaine Abuse</condition>
  <condition>Opiate Dependence</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modafinil 200mg / Methadone Maintenance (1.2mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modafinil 400mg/ Methadone Maintenance (1.2mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Citalopram 20/ Methadone Maintenance 1.2mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Citalopram 40/ Methadone Maintenance 1.2 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given to methadone-maintained subjects (1.2mg/kg) for the duration of the 12-week study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil 200mg</intervention_name>
    <description>10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1/2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil 400mg</intervention_name>
    <description>10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram 20mg</intervention_name>
    <description>10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram 40mg</intervention_name>
    <description>10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets cocaine abuse and dependence criteria (as determined by the SCID)

          -  Meets opiate dependence criteria (as determined by the SCID)

          -  In good general physical and psychiatric health (except for possible acute drug use
             related problems)

        Exclusion Criteria:

          -  Meets diagnostic criteria for other psychiatric disorders, including other forms of
             drug dependence (other than nicotine)

          -  Current cardiovascular disease (as determined by an electrocardiogram)

          -  Circumstances will not allow for completion of study (on probation or parole)

          -  Ethical constraints of supervision do not allow confidentiality (on probation or
             parole)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joy M Schmitz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>F. Gerard Moeller, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas Medical School at Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura B Madden-Fuentes, B.A.</last_name>
    <phone>713-500-2563</phone>
    <email>Laura.MaddenFuentes@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ann Garcia, MA</last_name>
    <phone>713-500-2804</phone>
    <email>Ann.D.Garcia@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Garcia, MA</last_name>
      <phone>713-500-2804</phone>
      <email>Ann.D.Garcia@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Meisch, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>December 11, 2009</last_update_submitted>
  <last_update_submitted_qc>December 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Joy Schmitz, Ph.D.</name_title>
    <organization>University of Texas Medical School at Houston</organization>
  </responsible_party>
  <keyword>Cocaine Abuse</keyword>
  <keyword>Opiate Abuse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Opiate Alkaloids</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 1, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

